Search

Your search keyword '"Dahan, Laetitia"' showing total 9 results
Start Over Author "Dahan, Laetitia" Journal european journal of cancer
9 results on '"Dahan, Laetitia"'

1. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

Author

Lepage, Côme, primary, Phelip, Jean-Marc, additional, Lievre, Astrid, additional, Le-Malicot, Karine, additional, Dahan, Laetitia, additional, Tougeron, David, additional, Toumpanakis, Christos, additional, Di-Fiore, Frédéric, additional, Lombard-Bohas, Catherine, additional, Borbath, Ivan, additional, Coriat, Romain, additional, Lecomte, Thierry, additional, Guimbaud, Rosine, additional, Petorin, Caroline, additional, Legoux, Jean-Louis, additional, Michel, Pierre, additional, Scoazec, Jean-Yves, additional, Smith, Denis, additional, and Walter, Thomas, additional

Published
2022
Full Text
View/download PDF

2. Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Author

Bang, Yung-Jue, primary, Golan, Talia, additional, Dahan, Laetitia, additional, Fu, Siqing, additional, Moreno, Victor, additional, Park, Keunchil, additional, Geva, Ravit, additional, De Braud, Filippo, additional, Wainberg, Zev A., additional, Reck, Martin, additional, Goff, Laura, additional, Laing, Naomi, additional, Mi, Gu, additional, Oliveira, Joana M., additional, Wasserstrom, Heather, additional, and Lin, Chia-Chi, additional

Published
2020
Full Text
View/download PDF

3. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial

Author

Malka, David, primary, François, Eric, additional, Penault-Llorca, Frédérique, additional, Castan, Florence, additional, Bouché, Olivier, additional, Bennouna, Jaafar, additional, Ghiringhelli, François, additional, de la Fouchardière, Christelle, additional, Borg, Christophe, additional, Samalin, Emmanuelle, additional, Bachet, Jean-Baptiste, additional, Raoul, Jean-Luc, additional, Miglianico, Laurent, additional, Bengrine-Lefèvre, Leila, additional, Dahan, Laetitia, additional, Lecaille, Cédric, additional, Aparicio, Thomas, additional, Stanbury, Trevor, additional, Perrier, Hervé, additional, Cayre, Anne, additional, Laurent-Puig, Pierre, additional, Gourgou, Sophie, additional, Emile, Jean-François, additional, and Taïeb, Julien, additional

Published
2019
Full Text
View/download PDF

5. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

Author

Neuzillet, Cindy, primary, Casadei Gardini, Andrea, additional, Brieau, Bertrand, additional, Vivaldi, Caterina, additional, Smolenschi, Cristina, additional, Brandi, Giovanni, additional, Tougeron, David, additional, Filippi, Roberto, additional, Vienot, Angélique, additional, Silvestris, Nicola, additional, Pointet, Anne-Laure, additional, Lonardi, Sara, additional, Rousseau, Benoît, additional, Scartozzi, Mario, additional, Dahan, Laetitia, additional, Aprile, Giuseppe, additional, Boussaha, Tarek, additional, Malka, David, additional, Crusz, Shantini M., additional, Le Sourd, Samuel, additional, Meurisse, Aurélia, additional, Lièvre, Astrid, additional, Vernerey, Dewi, additional, Evesque, Ludovic, additional, Heurgué, Alexandra, additional, Desramé, Jérôme, additional, Lecomte, Thierry, additional, Cacheux, Wulfran, additional, Bachet, Jean-Baptiste, additional, Phelip, Jean-Marc, additional, Hautefeuille, Vincent, additional, Hammoudi, Nassim, additional, Mary, Florence, additional, Locher, Christophe, additional, Bidault-Thirot, Anne, additional, Marthey, Lysiane, additional, Touchefeu, Yann, additional, Moulin, Valérie, additional, Zaanan, Aziz, additional, Taïeb, Julien, additional, Casagrande, Mariaelena, additional, Murgioni, Sabina, additional, Santini, Daniele, additional, Fornaro, Lorenzo, additional, Montagnani, Francesco, additional, Leone, Francesco, additional, Faloppi, Luca, additional, Giommoni, Elisa, additional, Lutrino, Stefania Eufemia, additional, Palloni, Andrea, additional, Brunetti, Oronzo, additional, Bergamo, Francesca, additional, Vasile, Enrico, additional, and Propper, David, additional

Published
2019
Full Text
View/download PDF

6. Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX

Author

Lledo, Gérard, primary, Huguet, Florence, additional, Chibaudel, Benoist, additional, Di Fiore, Frédéric, additional, Mineur, Laurent, additional, Galais, Marie-Pierre, additional, Artru, Pascal, additional, Blondin, Valérie, additional, Dupuis, Olivier, additional, Abdiche, Menouar Samir, additional, Jovenin, Nicolas, additional, Pozet, Astrid, additional, Bonnetain, Franck, additional, Attia, Mohamed, additional, Dahan, Laetitia, additional, and de Gramont, Aimery, additional

Published
2016
Full Text
View/download PDF

7. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial

Author

Ducreux, Michel, primary, Dahan, Laetitia, additional, Smith, Denis, additional, O’Toole, Dermot, additional, Lepère, Céline, additional, Dromain, Clarisse, additional, Vilgrain, Valérie, additional, Baudin, Eric, additional, Lombard-Bohas, Catherine, additional, Scoazec, Jean-Yves, additional, Seitz, Jean-François, additional, Bitoun, Laurence, additional, Koné, Sébastien, additional, and Mitry, Emmanuel, additional

Published
2014
Full Text
View/download PDF

8. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study

Author

Barbare, Jean-Claude, primary, Bouché, Olivier, additional, Bonnetain, Franck, additional, Dahan, Laetitia, additional, Lombard-Bohas, Catherine, additional, Faroux, Roger, additional, Raoul, Jean-Luc, additional, Cattan, Stéphane, additional, Lemoine, Alain, additional, Blanc, Jean-Frédéric, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Cazorla, Sophie, additional, Gargot, Dany, additional, Thevenot, Thierry, additional, Diaz, Emmanuel, additional, Bastie, Anne, additional, Aparicio, Thomas, additional, and Bedenne, Laurent, additional

Published
2009
Full Text
View/download PDF

9. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma

Author

Bonnetain, Franck, Dahan, Laetitia, Maillard, Emilie, Ychou, Marc, Mitry, Emmanuel, Hammel, Pascal, Legoux, Jean-Louis, Rougier, Philippe, Bedenne, Laurent, and Seitz, Jean-François

Subjects
*QUALITY of life, *CANCER patients, *PANCREATIC cancer, *HEALTH outcome assessment, *DRUG efficacy, *CANCER treatment, *ADENOCARCINOMA, *EVALUATION of clinical trials, *PANCREATIC tumors, *ANALYSIS of variance, *CHI-squared test, *FISHER exact test, *METASTASIS, *U-statistics, *DATA analysis, *DIAGNOSIS
Abstract

Abstract: Background: The Fédération Francophone de Cancérologie Digestive phase III trial in patients with metastatic pancreatic adenocarcinoma comparing 5FU, folinic acid and cisplatin combination followed by gemcitabine (Arm A) versus the opposite sequence (Arm B) failed to demonstrate a benefit in overall survival. To longitudinally compare the quality of life (QoL) we explored different definitions of time until definitive deterioration (TUDD) of QoL scores according to minimal clinically important difference (MCID) cut-offs. Methods: QoL was evaluated using the EORTC QLQ-C30 every 8 weeks until death. The following scores were analysed: global health, emotional functioning, physical functioning, fatigue and pain. TUDD was defined as the time interval between randomisation and the first occurrence of a decrease in QLQ-C30 score ⩾5 points without any further improvement in QoL score ⩾5 points or any further available QoL data. Analyses were repeated using a 10 point MCID and/or including death as event. Results: From 08/2003 to 05/2006, 102 patients in Arm A and 100 in Arm B were included. Using a 5 and a 10 point MCID, TUDD curves of the 5 scores did not differ according to treatment arm., The median TUDD of global health was 5.2 months (4.3–6.2) in Arm A and 6.1 months (5.1–8.5) in Arm B (log-rank p =0.50) including death as an event for a 5 point MCID. Multivariate Cox model showed that tumour localisation and progression were independently associated with TUDD (p <0.05). Conclusions: The strategy of chemotherapy did not influence the deterioration of QoL. The TUDD approach seems to provide meaningful clinical results that are adapted to metastatic pancreatic adenocarcinoma trials. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results